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Abstract

COST EFFECTIVENESS OF WARFARIN IN ANTICOAGULANT CLINIC AFTER
INTRODUCTION OF DABIGATRAN FOR STROKE PREVENTION IN ATRIAL
FIBRILLATION PATIENTS IN THE UNITED STATES
By Mai S. Alhazami, BS.
A thesis submitted in partial fulfillment of the requirements for the degree of Masters Science in
Pharmaceutical Sciences at Virginia Commonwealth University.
Virginia Commonwealth University, 2015.
Director: David Holdford, BSPharm., M.S., PhD, FAPhA
Professor, Department of Pharmacotherapy & Outcomes Science

OBJECTIVES: To assess cost effectiveness of anticoagulant clinics after FDA approval of New
Oral Anticoagulants (NOACs) for preventing ischemic stroke in Atrial Fibrillation (AF) patients
in the United States. METHODS: A decision tree was built to compare cost and effectiveness of
150mg dabigatran twice a day to adjusted dose of warfarin within anticoagulation clinic. The
analysis was for one year using a societal perspective. The population in this analysis was a
cohortofAFpatients,≥65yearsold,witha CHADS2 score>2, and no contraindication to
anticoagulation. RESULTS: The base case analysis showed that changing from warfarin with
anticoagulant clinic to dabigatran without monitoring resulted in an additional $82,793 per
QALY saved. Sensitivity analyses found that the model was sensitive to utilities of patients on
warfarin. CONCLUSION: This study showed that substituting dabigatran for warfarin in this
population was not within acceptable willingness to pay values for new therapy.

Chapter I: Introduction
Section 1.1: Background

Atrial Fibrillation (AF):
Atrial fibrillation (AF) is considered one of the most common sustained cardiac arrhythmias in
clinical practice. Statistics show that it affects more than 2.2 million Americans.1 One of the most
common complications of AF is Ischemic Stroke (IS). Approximately 15 percent of strokes are a
result of AF.2 Independently, AF increases the risk of IS 5 fold among all ages.3

Risk of IS increases in AF patients with advancing age, hypertension, heart failure, diabetes
mellitus, history of previous stroke or Transit Ischemic Attack (TIA),vascular disease, and
female sex. 3 According to the latest report of Heart Disease and Stroke Statistics, the percentage
of strokes related to AF increases from 1.5% at 50 to 59 years of age to 23.5% at 80 to 89 years
of age.3 Previous stroke or TIA is considered a strong independent predictor of stroke among AF
patients with a relative risk of 1.9 to 3.7.4 AF patients with hypertension and diabetes mellitus
have a relative risk of stroke of 1.7 compared to non- hypertension and non-diabetics patients.4
AF patients with cardiac failure have relative risk of 1.4 for stroke.4

There are several indexes that help to estimate stroke risk in patients with AF. The most
commonly used index is CHADS2 score which is a validated scheme for stratifying stroke risk in
AF patients.1,5 The CHADS2 score is a number from 0 to 6, where 0 is lowest risk and 6 is
1

highest risk. Stroke risk is calculated depending on the following risk factors: congestive heart
failure history,hypertensionhistory,age≥75,diabetesmellitus,andhistory of stroke or TIA
symptoms. Presentation of each risk factor adds 1 point to the total CHADS2 score with the
exception of history of a previous stroke which adds 2 points.6

AF patients who have experienced a stroke have higher mortality rates.1 Moreover; stroke can
affectapatient’squalityoflifeasitmaycausedifferenttypesofdisabilities,suchasvision
impairment, inability to walk without assistance, cognitive deficits, and depression. Stroke
complications are associated with socioeconomic burden on both individuals and the healthcare
system. In the United States, the mean lifetime cost per patient with an IS has been estimated at
$140,048.1 Inpatient care is considered the main cost driver, accounting for 70% of costs in the
first year after a stroke.1 After the first year of survival, costs of lost productivity and
rehabilitation can be significant. According to the U.S. Centers of Disease Control (CDC), the
estimated direct and indirect cost associated with stroke in the US 2010 was $53.9 billion
dollars.7

Warfarin
Warfarin has long been the most common treatment for preventing stroke in AF patients at
higher risk for stroke (i.e., CHADS2 score≥1).WarfarinisaVitaminKAntagonist (VKA). The
synthesis of clotting factors II, VII, IX, and X and the anticoagulant proteins C and S depend on
vitamin K, and warfarin acts as an anticoagulant by antagonizing vitamin K and thus inhibits
synthesis of these clotting factors.8Warfarin has been used since the 1940’s.9 Studies have
shown it to be effective in preventing stroke in AF patients and relatively inexpensive.8 However,
warfarin is under-utilized in the general practice. It is estimated that almost one third to one half
2

of all eligible AF patients do not receive warfarin.9 According to the Agency of Health Care
Policy and Research, underuse of warfarin in AF patients results in 40,000 preventable strokes in
the US each year at a cost of $600 million annually.10

A major reason for the sub optimal use of warfarin is its narrow therapeutic range and potential
for negative side effects. Effective treatment with warfarin requires patients to be maintained
within a narrow International Normalized Ratio (INR) range of 2 to 3. Maintenance of that range
requires continuous monitoring and potential dosing changes due to pharmacokinetic properties
of warfarin. The difficulty of warfarin dosing and monitoring is complicated by many drug and
food interactions. For example, anticoagulation effects of warfarin may decrease when taken
with food rich in vitamin K such as broccoli, asparagus, or cabbage. Also, warfarin metabolism
involves CYP450 isozymes, so concomitant administration of any CYP450 inducers like
phenytoin or cigarette smoking may decrease the effect of warfarin. Inhibitors like acyclovir may
increase effect of warfarin. These drug and food interactions may influence the pharmacokinetics
of the drug in the body, or they may worry patients and reduce their adherence behavior.11
Inadequate dosing of warfarin can increase the potential for stroke, while overdosing increases
risk of bleeding.

Anticoagulation Clinics
In 1996, Rosendaal reported that extensive monitoring of oral anticoagulation therapy by
individuals in specialized anticoagulation clinics improves the effectiveness and reduces
complications associated with oral anticoagulation therapy.10 The American College of Chest
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Physicians emphasized on the important role of anticoagulant clinics in improving quality of care
of patients on warfarin treatment.10

The anticoagulant clinic offers various services in order to enhance health outcomes of patients
on anticoagulant treatment. It involves conducting necessary laboratory tests, continuous follow
up for patients on anticoagulant treatment, and patient’seducation.12 These activities may differ
between one clinic to another depending on the setting used and clinical standards. The
anticoagulant clinics are usually delivered by pharmacists or nurses and considered the most
common service offered by outpatient pharmacists.13 In the United States most of the
anticoagulant clinics are run by pharmacists. It has been estimated that approximately 60% of
anticoagulant clinics in US are managed by pharmacists.14

Studies have shown that the pharmacist-managed anticoagulant clinics are cost effective
compared to usual care. Elaine Chiquette et al. concluded that anticoagulation control is
improved by the pharmacist run anticoagulant clinics and saved $162,058 per 100 patients
annually.10 Despite the effectiveness of these clinics, most warfarin patients are not followed by
anticoagulant clinics.15 Only 30-40% of AF patients on warfarin attend the anticoagulant clinic.14

New Oral Anticoagulation Medications
In recent years, novel anticoagulant agents have entered the US market with the potential to
dramatically impact anticoagulation clinics and other anticoagulation services. These
medications are Dabigatran, Rivaroxaban, and Apixaban.

4

Dabigatran was the first new oral anticoagulation agent approved by FDA in 2010. While
warfarin works by inhibiting of first step in the coagulation cascade, dabigatran works by
inhibiting a second step (figure 1.1). Dabigatran etexilate is a reversible direct thrombin
inhibitor. It inhibits coagulation by preventing thrombin-mediated effects including cleavage of
fibrinogen to fibrin monomers, activation of factors V, VIII, XI, XIII and inhibition of thrombininduced platelet aggregation.

The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial investigated
the efficacy and safety of dabigatran (110mg twice daily, 150mg twice daily) compared to an
adjusted dose of warfarin in 18,113 AF patients for a period of 2 years.16 Based on this study,
dabigatran 150mg was found to be better in preventing strokes compared to warfarin (P <0.001),
while the 110mg dose was similar to warfarin (P <0.35). However regarding the safety profile
dabigatran 150 mg had higher risk for Gastrointestinal (GI) bleeding (P <0.001) compared to
warfarin, while 110mg was similar to warfarin (P = 0.43). Both doses showed significantly lower
Intracranial Hemorrhage (ICH) compared to warfarin (P <0.001). For the risk of developing
Myocardial infarction (MI), dabigatran 150 mg showed higher risk compared to warfarin (P =
0.048), while 110 mg had similar risk as warfarin (P = 0.07).

Based on these results, only the 150 mg dose was approved by FDA. In this study dabigatran has
not been studied in patients with severe renal impairment, as patients with a Creatinine Clearance
(CrCl) less than 30 mL/min were excluded from RE-LY. FDA approved a dose of 75 mg of
dabigatran for patients with renal impairment. Dabigatran is approved for stroke prevention in
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AF patients, treatment and prevention for deep vein thrombosis (DVT) and pulmonary
embolism.

Recently on May 2014, FDA had reported the results of a study conducted by them on more than
134,000 Medicare patients.17 In this study they measured the safety and effectiveness profile of
dabigatran compared to warfarin in almost similar population as the RELY trial. Their findings
were consistent with the RELY trial, except for probabilities of developing MI with dabigatran
150 mg and warfarin. In contrast to RELY trial, this study had reported that there is no
significant difference in the probabilities of developing MI between two treatment options.

Following dabigatran, FDA approved rivaroxaban in 2011 as a treatment to prevent stroke in AF
patients. Rivaroxaban is a factor Xa inhibitor, and it prevents stroke by inhibiting platelet
activation and fibrin clot formation via direct, selective and reversible inhibition of factor Xa.

The efficacy and safety of rivaroxaban were evaluated in Rivaroxaban Once Daily Oral Direct
Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and
Embolism Trial in Atrial Fibrillation (ROCKET-AF) trial.18 It compared rivaroxaban 20 mg once
a day (reduced to 15 mg a day for patients with a CrCl of 30 to 49 mL/min) to an adjusted dose
of warfarin in 14,269 patients with AF for an average period of 1.6 years. Rivaroxaban was
shown to be similar to warfarin in preventing stroke (P =0.12) and MI (P = 0.12). It was found to
have superior effect in reducing ICH compared to warfarin (P =0 .02). However, for GI
bleeding, rivaroxaban had significantly higher risk compared to adjusted dose of warfarin (P
<0.001).
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A once daily dose of 20mg of rivaroxaban was approved by FDA for patients with CrCl >50
mL/min and a 15mg once daily dose for patients with a CrCl between 15–50 mL/min to prevent
stroke in AF patients. Moreover, FDA approved rivaroxaban for preventing stroke for postoperative thrombophylaxis Deep Vein Thromboembolism (DVT), and Pulmonary Embolism
(PE).

Apixaban is a factor Xa inhibitor approved by FDA in 2013 for stroke prevention in AF patients.
It prevents stroke with a similar mechanism of action to rivaroxaban.

In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation
(ARISTOTLE) trial, the efficacy and safety of apixaban was assessed.19 Apixaban was found to
be superior to warfarin for preventing stroke (P = 0.01). GI bleeding and MI was similar to
warfarin (P= 0.37 for both events). Risk of ICH was significantly lower in apixaban patients
compared to warfarin (P<0.001). Apixaban 5mg twice daily was approved by FDA to prevent
stroke in patient with AF, treatment and prevention for DVT and pulmonary embolism.

A 2012 study looking at the potential for switching warfarin to new oral anticoagulants (NOACs)
found that more than 60% of patients in Johns Hopkins anticoagulation clinics could do so.20

Despite the effectiveness and safety of NOACs compared to warfarin, they face challenges to
replace warfarin. NOACs are considered to have higher acquisition cost compared to warfarin.
NOACs are also mainly excreted by kidney and may not be appropriate in renal impairment
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unlike patients treated with warfarin. Apixaban may be a relatively safer option with renal
impairment as it is excreted via multiplies pathways. Furthermore, there is little evidence of the
long term effect of NOACs, and there is no antidote to reverse effect of these drugs, unlike
warfarin. So adoption and usage for NOACs may depend heavily on its perceived economic
value.

Section 1.2: Objectives
1. Calculate costs and Quality Adjusted Life Years (QALYs) associated with treatment of AF
patient with dabigatran 150mg BID and adjusted dose of warfarin within pharmacistmanaged anticoagulant clinic.
2. Build a decision tree model with the 2 therapeutic approaches and map out associated
outcomes.
3. Evaluate the cost effectiveness of dabigatran 150mg BID compared to adjusted dose of
warfarin within pharmacist-managed anticoagulant clinics.

Section 1.3: Rationale
Studies addressing the cost effectiveness of NOACs compared to warfarin have used similar
models and outcome measurements. Most of the previous studies built Markov model with
almost similar health states and time horizons. Moreover, they only used single source as a
reference for their probabilities.
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Furthermore, there were limited studies that account for INR control level in their cost
effectiveness analysis. There is lack of studies that directly assessed cost effectiveness of
NOACs to warfarin treatment within anticoagulant clinic settings.

Because the dabigatran was the first NOACs introduced into the US market and so it is assumed
to be well utilized, it was chosen in the present analysis to represent NOACs. Moreover there are
more available data regarding dabigatran compared to other NOACs.

Based on the available literature, this is the first study that compared directly between dabigatran
and warfarin treatment within pharmacist-managed anticoagulant clinic. This study will enable
us to answer the question about the future of these clinics after introduction of NOACs into the
market, especially as they do not require monitoring like warfarin. Finally in this study, we tried
to obtain probabilities data from a secondary source and test it in the sensitivity analysis.

9

Figure1.1: Mechanism of action of oral anticoagulants 21
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Chapter II: Literature review and discussion of decision analysis
Section 2.1: Literature review

In order to assess cost effectiveness of NOACs compared to warfarin in usual care setting and
anticoagulant clinic, we need to evaluate what is there in the literature. This was done in two
steps. First, studies that looked at the effectiveness and cost effectiveness of warfarin in usual
care versus anticoagulant clinic were evaluated. Based on the literature, we hypothesized that
anticoagulant clinic is more cost effective compared to usual care.

Then, the effectiveness and cost effectiveness of NOACs versus warfarin in anticoagulant clinic
were assessed. This part was done under the assumption that patients treated with NOACs do not
need a follow up in an anticoagulant clinic. According to study done by Lee, et al. that looked at
adherence rate and clinical outcomes of dabigatran in anticoagulant clinic versus usual care, they
concluded that neither the adherence rate nor the therapeutics outcomes differed between patients
in the two groups.22 So this study can support the assumption that NOACs do not required
monitoring by anticoagulant clinic in order to improve patient outcomes.
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Section 2.2: Systematic literature review on the effectiveness and cost effectiveness of
pharmacist-managed anticoagulant clinic compared to usual care
A systematic literature review was conducted on October 2014 using PubMed/MEDLINE,
CINAHL, ECONLIT and IPA. The search terms were combinations of: ("Warfarin" AND
"Anticoagulant clinic") AND ("Cost" OR "Costs"), ("Anticoagulant clinic" AND "pharmacy"),
("pharmacist managed Anticoagulant clinic"), ("pharmacist managed Anticoagulant service").
Titles and abstracts from search result articles were screened for using the following inclusion
criteria and exclusion criteria:
Inclusion criteria:
1. Assess cost-effectiveness of pharmacist-managed anticoagulant clinic.
2. Assess effectiveness of pharmacist-managed anticoagulant clinic.
3. Published in English.
4. Addressed patient with Atrial Fibrillation (AF).
5. Abstract is available.
Exclusion criteria:
1. Studies not conducted in the United States.
2. Studies compared aspirin or heparin to warfarin.

The search of the databases revealed a total of 1,293 articles. After eliminating duplicates and
applying inclusion and exclusion criteria, 57 research articles remained. 23-79 Out of these 57
articles, 6 articles were chosen to be discussed as they were the most recent studies, and had
more updated information. Moreover, these chosen articles were the most relevant to the
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inclusion criteria, while the other articles were either focusing only on the cost of anticoagulant
clinic compared to usual care or did not include a comparison group.29,31,40,54,61,72
Literature Summary
Most articles revealed by the literature review looked at the effectiveness of an anticoagulant
clinic compared to usual care for patients receiving warfarin therapy. Most did not indicate a
specific diagnosis for treated patients; including patients with AF and other indication who are
on warfarin.
Five articles compared the effectiveness of anticoagulant clinics compared to usual care, and 1
article was a cost-effectiveness analysis of an anticoagulant clinic compared to usual care
(Tables 2.1 and 2.3).

One of the 5 effectiveness articles, by Nichol et al. (2008), specified AF patients.61 The study
was a retrospective observational cohort that used claim data of a physician group practice.
Using International Classification of Diseases Ninth Revision code (ICD-9), they identified AF
patients on warfarin and having more than 1 INR test between March 2001 to March 2004.
Patients were excluded if they had more than a one year gap between 2 INR tests.

Usual care in this study consisted of patients treated by a care team which included primary care
physicians and nurses but which had no standardized protocol of care. Patients treated in the
anticoagulant clinic were managed by similar care team guided by a standardized warfarin
management protocol. Any patients treated with warfarin were eligible to be referred to an
anticoagulant clinic. Patients included in this study were either treated with usual care or
attended an anticoagulant clinic, with no crossover between two groups.
13

The outcome measures used to assess quality were time spent in therapeutic range (INR 2-3) and
time to first occurrence of major bleeding or stroke. A t-test compared time spent in therapeutic
range between the 2 groups, and a Kaplan Meier survival analysis compared rates of bleeding or
stroke.

The study found that the 351 patients in the anticoagulant clinic spent significantly more time in
therapeutic range compared to the 756 patients in the usual care group. Rates of major bleeding
and stroke were lower, but not statistically so, in the anticoagulant clinic group compared to
usual care.

Some studies in the literature have assessed the effectiveness of anticoagulant clinics managed
by pharmacists compared to usual care; but are not specific to AF patients (i.e. several
indications of warfarin). Chiquette E, et al. compared 142 newly treated anticoagulant patients in
usual care to 176 newly treated patients in an anticoagulant clinic.31 The outcome measures were
anticoagulant control (time within therapeutic range), bleeding, thromboembolism events, and
cost of hospitalization and emergency room (ER) visit. Based on the results of this study,
patients treated in an anticoagulant clinic had lower rates of significant bleeding, major to fatal
bleeding, thromboembolism events, and significantly lower annual rates of hospitalization and
ER visits related to warfarin treatment.

A recent article by Hall, et al. in 2011 evaluated differences in health care expenditures and the
clinical outcomes between usual care and a pharmacist-managed anticoagulant clinic.40 Using
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data from the University of Pittsburg Medical Center (UPMC), they reviewed 175 patients in
each group of which 60% were AF patients. They looked at cost, medical outcomes, and patient
compliance. Direct, overall medical and operational costs were included when measuring costs.
The therapeutic outcomes were adverse events, percentage of INR within therapeutic range, time
spent within therapeutic range, and ER visits. Patient compliance was measured by calculating
the Medication Possession Ration (MPR). Similar to Chiquette E, et al., authors reported that
patients in the anticoagulant clinic had significantly higher therapeutic INR rates and spent
longer time in this range compared to usual care. Anticoagulant clinic patients experienced fewer
adverse events and ER visits.

Locke, et al. (2005) explored the difference in adverse events related to warfarin treatment in
pharmacist-managed anticoagulant clinics and usual care.54 Using a before and after research
design, 420 patients in a community hospital outpatient anticoagulant clinic were discontinued
from an anticoagulation clinic program and assigned to usual care. Authors found that patients
discontinued from the clinic experienced significantly more adverse events related to warfarin
treatment compared to those treated with pharmacist-managed anticoagulant clinic.

One study was less compelling for the benefits of an anticoagulation clinic in managing warfarin
therapy. It compared patient outcomes in pharmacist managed anticoagulant clinic (n=41) to
usual care (n=75).29 In contrast to previous studies, no statistical significant difference was
detected in the rate of adverse events or ER visits between two groups, although the percentage
of anticoagulant clinic patients within therapeutic ranges was significantly higher. The absent of
statistical significant can be due to the small sample size in each groups.
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A study by Sullivan et al. evaluated the cost-effectiveness of a pharmacist-managed
anticoagulant clinic compared to usual care for AF patients with high risk of stroke.72 The
analysis used a semi-Markov model to compare usual care and clinic services using a societal
perspective. A cohort of AF patients similar to the SPORTIF (Stroke Prevention using Oral
Thrombin Inhibitor in atrial Fibrillation) III and V trials was used.

They found that anticoagulation monitoring services improved effectiveness by 0.057 QALYs
and cost $US2100 less, and therefore dominated usual care. Their sensitivity analysis found that
the results were sensitive to the risk of all strokes and systemic embolic events associated with
usual care, but were robust with other input variables. Moreover, a Monto Carlo simulation
showed robust results in favor of anticoagulation management services dominating usual care in
91% of possible circumstances.

In summary, the literature suggests that AF patients receiving warfarin and managed in
anticoagulation clinics have better therapeutic control over their INRs, less adverse events, fewer
health care visits for warfarin related causes, and lower costs of care.
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Section 2.3: Systematic literature review on the effectiveness and cost effectiveness of
NOACs compared to warfarin in pharmacist-managed anticoagulant clinic
Systematic literature review was conducted on October 2014. PubMed/MEDLINE, CINAHL,
ECONLIT and IPA were used for literature search with combination of the search terms:
("Warfarin") AND ("Anticoagulant" OR "Anticoagulants") AND ("Cost" OR "Costs"),
("Warfarin") AND ("Apixaban" OR "Dabigatran" OR "rivaroxaban") AND ("Cost" OR "Costs"),
("Anticoagulant clinic") AND ("NOACs" OR "Apixaban" OR "Dabigatran" OR "rivaroxaban").
Titles and abstracts were first screened for inclusion criteria and exclusion criteria. The inclusion
and exclusion criteria that were applied are defined as the following:
Inclusion criteria:
1. Assess effectiveness of NOACs compared to warfarin.
2. Assess cost-effectiveness of NOACs compared to warfarin.
3. Published in English.
4. Addressed patient with AF.
5. Abstract is available.
Exclusion criteria:
1. Studies not conducted in the United States.
2. Studies compared NOACs with aspirin or heparin.

A search of the 4 databases revealed a total of 2,989 articles. After eliminating duplicates and
applying inclusion and exclusion criteria, a total of 21 research articles were found. 22,80-99 Out of
21 articles 13 articles were chosen to be discussed, as they were most relevant to the search
criteria, and available.80,83,84,87,88,90-96,98
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Literature Summary
Thirteen articles were identified as relevant to this research. Five compared effectiveness and
safety of NOACs to warfarin (Table 2.2).80,87,90,96,98 The 8 remaining articles assessed cost
effectiveness of NOACs compared to warfarin. 83,84,88,91-95,97

One of the 5 effectiveness studies compared all three NOACs to warfarin.98 In this study, the
authors searched a clinical trials database and found 3 large clinical trials comparing NOACs to
warfarin (ARISTOTLE for apixaban, RELY for dabigatran, and ROCKET-AF for rivaroxaban).
98

Almost similar inclusion/exclusion criteria were used for all three trials. Efficacy was

determined by rates of developing stroke or Systematic Embolism (SE). Safety was measured in
the RELY and ARISTOTLE studies by major bleeding events, while the ROCKET-AF trial
measured major and non-major bleeding. The analysis indicated that there were no significant
differences in efficacy between the 3 NOACs. Regarding safety profile, apixaban showed a
significantly lower rate of major bleeding compared to dabigatran and rivaroxaban. No
significant difference between the 3 NOACs was found in all-cause mortality. Overall, the 3
NOACs produced almost similar effects in reducing stroke in AF patients with higher risk of
stroke, however, the apixaban was the safest.

The remaining 4 studies compared the effectiveness of apixaban to warfarin by using the data
from the ARISTOTLE trial. Amin et al. estimated the real world rate of stroke and bleeding of
apixaban in AF patients.80 Authors used a Medco claims database to identify AF patients with
CHADS2 score≥1andtreatedwithwarfarin.Theycalculatedrateofstrokeandbleeding
associated with warfarin. By using the Relative Risk Reduction (RRR) from ARISTOTLE trial,
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they estimated events that can be avoided if apixaban was used instead of warfarin in the real
world. The analysis showed that event rates associated with warfarin were higher in the real
world compared to ARISTOTLE trial, and the clinical benefit of apixaban might be greater in the
real world compared to a clinical trial. However, this is an extrapolation of results from the
clinical trial and so may not reflect the true apixaban effect in the real world practice. Further
studies using real world data are needed.

In addition to these articles, the literature review revealed 8 studies that evaluated costeffectiveness of NOACs compared to warfarin (Table 2.3).83,84,88,91-95,97 There were a lot of
similarity in the method and model building in the 8 studies. They all used Markov models with
almost similar health states: well, ICH, Extracranial Hemorrhage (ECH), IS, MI, minor bleeding,
and death. Cost/QALY was the outcome measure in all of the 8 studies. The analysis was either
done from societal perspective83,88,91-93 or US payer/Medicare perspective84,94,95,97 . The input
transition probabilities were obtained mainly from the three major clinical trials (ARISTOTLE,
RELY, ROCKET-AF). The populations of all the 8 studies were chosen to be similar to clinical
trials.

Overall, there were 2 studies that assessed cost effectiveness of all the 3 NOACs compared to
warfarin in one model.83,91 The literature mostly suggested that NOACs are more cost effective
compared to warfarin. Harrington, et al. found that all the 3 NOACs produced a greater QALY
compared to warfarin.91 At willingness to pay threshold of $50,000 per QALY gained, all the 3
NOACs are cost effective compared to warfarin. However, a study done by Canestaro, et al.
found that at a willingness to pay of $100,000 only the apixaban is cost effective compared to
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warfarin, although all of the 3 NOACs may produce higher efficacy relative to warfarin.83
Despite that these 2 studies were using similar models, the Harrington model did not account for
ECH as health state and that can explain why the result was favorable to all of the 3 NOACs.

The literature review revealed two studies that evaluated specifically cost effectiveness of
apixaban compared to warfarin. Both studies found that apixaban is a cost effective strategy
relative to warfarin.92,94 The cost data of apixaban were different in the two studies as the
apixaban was not yet approved in the US market at the time of the analyses. One study used the
UK price of apixaban92, while the other study assumed it had a similar cost as dabigatran.94
Rivaroxaban cost effectiveness was compared to warfarin in a study by Lee et al.95 The authors
reported that rivaroxaban has a higher cost and higher QALY. The base case analysis revealed
that rivaroxaban is cost effective compared to warfarin from Medicare perspective with an ICER
value lower than willingness to pay of $50,000 per QALY gained.

Three studies evaluated cost effectiveness of dabigatran versus warfarin.84,88,93,97 Kamel, et al.
found that dabigatran is cost effective, unless the INR is well control with warfarin treatment.93
A study by Freeman, et al. was done before dabigatran was approved in US market, so they used
the UK price of the dabigatran in their analysis.88 The base case analysis revealed that dabigatran
is cost effective compared to warfarin; however this result was sensitive to the cost of
dabigatran.88 Clemens, et al. looked at cost effectiveness of dabigatran in different age groups
(patients<75yearsold,≥75 years old, and all patients). The authors found that dabigatran is cost
effective regardless age group.84
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In summary, the literature indicates that NOACs are more effective and more costly compared to
warfarin, and that the cost effectiveness of NOACs depends on level of INR control with
warfarin treatment.
Section 2.4: Gaps in Literature
This literature review found that it is not clear whether anticoagulation clinics are needed any
longer after introduction of NOACs. In general, warfarin is less cost effective using clinical trial
data but it is not clear if similar results will be seen in regular practice settings. It is also not clear
whether anticoagulation clinics or similar intensity services were used in clinical trials. In
addition, the costs of providing anticoagulation services were not adequately described in the
studies. Moreover, all the studies had used one source to obtain the probabilities for each event.

Finally, no study clearly investigates how patients might benefit from an anticoagulant clinic if
they receive NOACs. So this study is the first study that looked at cost effectiveness of NOACs
compared to warfarin in anticoagulant clinic.
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Section 2.5: Discussion of decision analysis
Based on the literature review, the treatment with warfarin appears to be more cost effective in
anticoagulant clinics than usual care. The value of these clinics with the availability of NOACs is
not clear, so an economic model is needed to compare between patients treated with warfarin in
anticoagulant clinic versus NOACs. Dabigatran was chosen in this analysis to represent NOACs,
as it was the first one introduced into the US market and so assumed to be well utilized in the
healthcare facilities.

A decision tree model will enable us to evaluate the cost effectiveness of warfarin within
anticoagulant clinics compared to 150 mg BID of dabigatran within time period of 1 year. The
decision tree was chosen to model the present analysis due to simplicity and lack of data
regarding long term safety and efficacy profile of dabigatran. The tree will assess most common
outcomes associated with each treatment strategy which are: well, IS, ICH, MI, GI bleeding,
dyspepsia, and death. The probabilities of each event will be mainly obtained from RELY
clinical trial or published literature.

In any cost effectiveness analysis, it is very important to clearly define the base case population.
In this study the population of interest is AF patients, age >65, with CHADS2 score≥2,andno
contraindication to anticoagulation.Patientswithcreatinine clearance of < 30 ml per minute or
with active liver disease will be excluded from the study population.

It is crucial to state the perspective that the study will take, as it can affect types of costs included
in evaluation. In this study the cost effectiveness of dabigatran compared to warfarin within
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anticoagulant clinic was assessed from a societal perspective. The decision tree will help to map
up all the resource utilized by each outcome (figure 2.1). The resources utilized were physician
visits, hospital admissions, INR monitoring and anticoagulant clinic visits with warfarin
treatment.

Various sensitivity analyses were carried out due to parameter and input uncertainty. Examples
of parameter uncertainty include probabilities of safety of each treatment strategy and cost of
anticoagulant clinic.
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Figure 2.1: Schematic representation of the decision model
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Table 2.1: Included articles from summary of literature comparing effectiveness of anticoagulant clinic to usual care
Authors/Year

Primary measures

Nichol et al.61 (2008)

-Time in therapeutic
range
- Time to first bleeding
event or stroke

Chiquette et al.31
(1998)

-Anticoagulation
control
-Development of
bleeding or stroke
-Cost of hospitalization
and ER visits
-Health care
expenditure
-Therapeutic outcomes
Number of adverse
events related to
anticoagulation
treatment
-Anticoagulation
control
- ER visit and
inpatients admission
related to stroke or
bleeding

Hall et al.40 (2011)
Locke et al.54 (2005)

Chamberlain et al.29
(2001)

Patient
characteristics
AF patients

Data source

Author’s conclusion

Medical and
pharmaceutical claims
data from Sharp ReesStealy (SRS) physician
group
All patients treated University healthcare
with warfarin
system

Anticoagulant clinic had positive impact on
anticoagulation management.

All patients treated University of Pittsburgh
with warfarin
Medical Center

Pharmacist run anticoagulant clinic reduced
health care expenditure and improved
therapeutics outcomes.
Pharmacist managed anticoagulant clinic
reduced adverse events related to warfarin.

All patients treated St.Joseph’sMedical
with warfarin
Center

All patients treated Family Medicine of
with warfarin
Southwest Washington
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Pharmacist run anticoagulant clinic
improved anticoagulation control, reduced
rate of bleeding and stroke, and reduced
hospitalization and ER visit costs.

Patients treated in anticoagulant clinic had
better anticoagulation control, however,
there are no statistical significant different
in rate of adverse events

Table 2.2: Included articles from summary of literature of effectiveness of NOACs
Authors/Year

Primary measures

Population
characteristics

Source data

Author’s conclusion

Real world rate of stroke
and major bleeding
associated with apixaban
Efficacy (stroke or SE) and
safety (major bleeding)
profiles

AF patients with CHADS2
score≥1

U.S. commercial and
Medicare health plans
(Medco claims database)
ARISTOTLE trial

Efficacy (stroke or SE) and
safety (major bleeding and
death from any cause)
profiles
Efficacy (stroke or SE) and
safety (major bleeding)
profiles according to
patients’CHADS2,
CHA2DS2VASc*, and
HAS-BLED scores**

AF patients with at least
one additional risk factor
for stroke

ARISTOTLE trial

AF patients with CHADS2
score≥1

ARISTOTLE trial

Apixaban might have a
better impact in real world
relative to warfarin
Absolute benefit of
apixaban is higher in
patients with previous
stroke compared to
warfarin
Apixaban had lower
stroke, SE, major bleeding,
and mortality compared to
warfarin
Apixaban had better safety
and efficacy profiles
compared to warfarin
regardless stroke risk
index

Apixaban
Amin et al.80 (2013)
Easton et al.87 (2012)

Granger et al.90 (2011)

Lopes et al.96 (2012)

AF patients with and
without previous stroke or
TIA

All NOACs
Schneeweiss et al.98 (2012)

Efficacy (stroke or SE) and AF patients with a
safety (major bleeding)
CHADS2 score≥3
profiles

* CHA2DS2VASc: score scale for AF patients with stroke risk
** HAS-BLED scores: score scale to estimates major bleeding risk for patients on anticoagulant
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RELY, ROCKET-AF ,
ARISTOTLE trials

There are non-significant
differences in efficacy
measures between 3
NOACs, but apixaban had
lower bleeding risk

Table 2.3: Included articles from summary of literature of cost effectiveness analysis
Authors/Year

Primary

Population

Model

Time

Perspective

Model results

Author’s conclusion

comparisons

characteristics

Usual care
vs. pharmacistmanaged
anticoagulation
monitoring
service

Cohort of 70 years
old AF patients
with higher risk of
stroke

SemiMarkov
model

10 years

Society

Anticoagulation
services enhanced
effectiveness by
0.057 QALYs and
cost $US2,100
less

Anticoagulation
management service is
cost-effective compared to
usual care

Kamel et al.93
(2012)

Dabigatran 150
mg twice-daily
vs.
adjusted dose
warfarin (INR
range 2-3)

Markov
model

20 years

Society

Dabigatran provided
additional 0.36
QALYs with
cost of $9,000
(ICER of $25,000)

Dabigatran is cost effective
compared to warfarin for
stroke prevention in AF
patients with history of
stroke or TIA

Freeman et al.88
(2011)

Dabigatran 110
mg twice, daily
vs.
dabigatran 150
mg twice, daily
vs.
adjusted dose
warfarin

Cohort of AF
patientsaged≥70
years
history of stroke
or TIA, and no
contraindication
to anticoagulation
Cohort of AF
patients≥65years
with CHADS2
score ≥1, and no
contraindications
to anticoagulation

Markov
model

Lifetime

Society

ICER of 150 mg
dabigatran was
$45,372 per QALY,
and $51,229 per
QALY for 110mg
dabigatran.

Dabigatran 150mg is costeffective compared to
warfarin

horizon

Anticoagulant clinic
Sullivan et al.72
(2006)

Dabigatran
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Authors/Year

Primary

Population

Model

Time

comparisons

characteristics

Dabigatran 150
mg twice daily
vs. warfarin

AF patients at age
<75 and at age
≥75

Markov

Lifetime

Rivaroxaban 20
mg/day vs.
adjusted dose
warfarin

Cohort of AF
patients≥65years
old, CHADS2
score of 3, no
contraindications
to anticoagulation

Markov

Lee et al.94
(2012)

Apixaban 5mg
twice daily vs.
adjusted dose
warfarin

Kamel et al.
92
(2012)

Apixaban 5mg
twice daily vs.
adjusted dose
warfarin

Cohort of AF
patients≥65years
old, CHADS2
score of 2.1, no
contraindications
to anticoagulation
Cohort of AF
patients of 70
years old, with
history of stroke,
and no
contraindications
to anticoagulation

Perspective

Model results

Authors conclusion

US Medicare
payer

ICER was $52,773,
$65,946, and
$56,131 for cohorts
<75,≥75,andAll
respectively

Dabigatran is cost-effective
compared to warfarin
regardless age group

Lifetime

US Medicare
payer

The ICER of
rivaroxaban was
$27,498 per QALY

Rivaroxaban is cost–
effective compared to
warfarin for stroke
prevention in AF patients

Markov

Lifetime

Medicare

Apixaban provided
additional 0.34
QALYs and
cost $2,633 less than
warfarin

Apixaban is cost-effective
alternative to warfarin

Markov

20 years

Society

The ICER for
apixaban was
$11,400 per QALY

Apixaban is cost-effective
compared to warfarin

horizon

Dabigatran
Clemens et al.84
(2014)

Rivaroxaban
Lee et al.95
(2012)

Apixaban
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Authors/Year

Primary

Population

comparisons

characteristics

Harrington et
al.91 (2013)

Apixaban 5 mg
vs. dabigatran
150 mg vs.
rivaroxaban 20
mg
vs. adjusted
dose warfarin

Canestaro et
al.83 (2013)

Apixaban 5 mg
vs. dabigatran
150 mg vs.
rivaroxaban 20
mg
vs. adjusted
dose warfarin

Cohort of AF
patients age 70
year old, with
CHADS2 ≥1,
renal CrCl ≥50
mL/min, and no
contraindications
to anticoagulation
Cohort of AF
patients of 70
years old, with
mean CHADS2 of
2, and no
contraindications
to anticoagulation

Model

Time

Perspective

Model results

Authors conclusion

horizon

NOACs
Markov

Lifetime

Society

Markov

Lifetime

Society
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Compared with
warfarin, apixaban
resulted in an
additional 0.5
QALYs at a cost of
$7,513, and ICER
of $15,026 per
QALY
ICER compared
with warfarin, for
dabigatran,
rivaroxaban, and
apixaban are
$140,557, $111,465,
and $93,062 per
QALY gained,
respectively

NOACs are all costeffective compared to
warfarin

At willingness to pay value
of $100,00, apixaban is the
cost effective strategy
compared to warfarin and
other NOACs

Chapter III: Method

Economic evaluation of warfarin in anticoagulant clinic versus dabigatran was done by following
the CHEERS (Consolidated Health Economic Evaluation Reporting Standards) guideline.100
Section 3.1: Model
In order to evaluate cost effectiveness of warfarin in anticoagulant clinic to dabigatran, a
decision tree model was built. Figure 3.1 illustrates the model. There are 2 possible alternatives
that a patient with AF might be treated with: adjusted warfarin dose with INR 2-3 in a
pharmacist-managed anticoagulant clinic or 150mg BID of Dabigatran. Each treatment option
might result in one of the following health states: well (with no complication), IS, ICH, GI
bleeding, MI, dyspepsia, or death from any cause. These health states were chosen in this model
as they were the most common complications reported in the RELY clinical trial and highly
expensive to treat.16 Each complication can either be treated or lead to patient death except for
dyspepsia.
The analysis was conducted from the societal perspective as it is consider appropriate for our
outcome measure (QALY). The reason behind conducting such analysis was to assist decision
makers to choose best anticoagulant strategy for AF patients. The target population of this
analysis was similar to the RELY trial population, which was cohort of AF patients,≥65years
old, with mean CHADS2 2.1, and no contraindication to anticoagulation. Patients with CrCl <30
mL/min and active liver disease were excluded from study population.
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The time horizon of the analysis was 1 year as probabilities reported in the RELY trial were
annual and because the period was sufficient to assess effectiveness and identify complications.

Outcome measures included in this study were reported in 2014 $US costs, QALYs, Incremental
Cost Effectiveness Ratios (ICERs), and Net Monetary Benefit (NMB). The primary measure for
treatment effectiveness was QALYs saved. QALY is common measure of effectiveness that
takes into account the quantity of years lived adjusted to its quality.101 It has been recommended
by the panel on cost-effectiveness in Health and Medicine as the preferred outcome measure.101
To calculate QALY, we multiply years lived by coefficient (between 0-1) which corresponds to
quality of life, such as utilities. For example, the QALY for 1 year equals utility of health state of
patient multiply by 1. The most common utility measures are time trade off (TTO), standard
gamble (SG), rating scale (RS), and health state classifications system such as EQ-5D.102,103 in
our analysis, utility of patients can be affected by the health state and type of anticoagulant
therapy. All analyses were done using TreeAge Pro 2014 software (Appendix A).
Several assumptions were made in the model:
1. Patients were assumed to be similar to those in the RELY clinical trial.16 The population
in this study were assumed to be AF patients with at least one of the following
conditions:
a. Previous stroke, TIA, or SE.
b. Age≥65yearswith diabetes mellitus, Coronary Artery Disease (CAD), or
hypertension.
c. Left Ventricular Ejection Fraction (LVEF) <40%.
d. Age≥75years.
31

e. Patients with symptomatic heart failure, New York Heart Association (NYHA)
Class≥2withinatlast6months.
2. Population of the study assumed to have mean CHADS2 score of 2.1, similar to the
RELY trial.
3. Probabilities of events for patients treated with warfarin and attending anticoagulant
clinic were assumed to be similar to patients treated with warfarin in RELY clinical trial.
This assumption was made as the patients in the RELY were monitored continuously
almost similar to the anticoagulant clinic setting.16
4. The dose of warfarin was assumed to be 5mg once daily for the cost calculation.
5. Generic warfarin was used.
6. Patients on warfarin were assumed to have 1 INR test monthly.
7. Cost of fatal IS, ICH, GI bleeding was assumed to be similar to the cost of death, due to
the lack of ICD 9 or DRG code.
8. Patients develop the event once through the study period.
9. Patients treated with dabigatran and who develop major bleeding (GI bleeding or ICH)
were assumed to discontinue treatment, and replace it with rivaroxaban 20 mg once daily.
This assumption was made according to different bleeding and anticoagulation
management guidelines. They stated that when the patient develops bleeding with
dabigatran then it should be discontinued immediately and substituted it with another
anticoagulant. Rivaroxaban was chosen as it has advantage of once daily dose.5

32

10. If patients experience any adverse events requiring discontinuation, the cost of dabigatran
would be for only six months and then rivaroxaban for the following six months of the
study period.
11. Patients on both treatment options were assumed to have only 1 physician visit
throughout the study period. In the physician visit the patients either get the referral to
anticoagulant clinic for patients on warfarin, or to get annual prescriptions of dabigatran.
12. Utility of patients treated with dabigatran was assumed to be similar to utility of those
treated with ximelagatran, an older direct thrombin inhibitor due to the lack information
about utility of patients on dabigatran.
13. Adherence rates for both treatment alternatives were assumed to be similar due to
insufficient data about adherence rate in patients on dabigatran.
14. Willingness to pay (WTP) was set to be $50,000 as it is the most common value used in
the economic analysis.

Section 3.2: Outcome data
The outcomes of this analysis were mainly obtained from the RELY clinical trial and
supplemented by other literature (Table 3.1, 3.2). The probabilities of adverse events were based
on data from the RELY clinical trial.16 Probabilities of MI for both treatment alternatives were
obtained from an updated report of the RELY trial.104 Probability of being on the treatment with
no change in the health state (well state) was calculated by subtracting sum of all the events
probabilities in the tree from 1. Mortality rates of IS, ICH, GI bleeding, and MI were estimated
from previous literature.83
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Patient’squalityoflifeorutilitymaybeaffectedbythetypeofanticoagulationtherapy.
Dabigatran has advantages over warfarin as the patients do not require continuous monitoring, or
food restriction and have fewer drug-drug interactions. The patients then may be less worried
and concerned about treatment.11 On the other hand, warfarin is less expensive than dabigatran
and had well established safety and efficacy profile.11 Thesefactorsmayaffectpatients’
preferences toward one medication over another.

Patient utilities for the different health states in the model were obtained from the published
literature. Utility of AF patients treated with warfarin was based on a study that estimated the
utility of AF patients treated with warfarin or aspirin.105 The time tradeoff and standard gamble
methods were used to calculate utilities of 83 AF patients. In our study the mean utility for
patients on warfarin therapy was used in the model. Due to lack of direct data regarding the
utility of patients on dabigatran, it was estimated to be similar to utilities of those treated with
ximelagatran, an older direct thrombin inhibitor, as seen in previous analysis.106 The utility of
dabigatran patients was greater than patients on warfarin as the dabigatran does not require
routine monitoring. By definition, utility of dead patients is zero. Utilities of patients
experiencing IS, GI bleeding, ICH, MI, or dyspepsia were obtained from previous literature.93,107

Section 3.3: Cost data
In this analysis all direct medical costs associated with both treatment branches were added in
the calculation (Table 3.3). The prices of the medicines (warfarin, dabigatran, and rivaroxaban)
were obtained from Virginia Commonwealth University hospital database. The prices used were
340B cost of the drugs. The 340B cost is drug discount program applied to certain eligible
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health care organizations and covered entities participating in the public health services such as
Medicare/ Medicaid allow them to get the outpatients drugs at reduced prices from
Manufacturers.108 The 340B cost was chosen in our model as they are considered a better
estimate of drug cost for our targeted population (age >65 years old) who are eligible to
Medicare.109

According to American College of Cardiology (ACA)/American Heart Association (AHA) and
the Heart Rhythm Society (HRS) guidelines for management of AF patients, the anticoagulation
drug should be discontinued immediately and the patient carefully monitored if bleeding occurs.5
In our study, if bleeding develops for the patients on warfarin therapy, then warfarin would be
immediately withdrawn and resumed after the bleeding is resolved, as the patients would still be
at risk of developing stroke. For patients on dabigatran, it is recommended that when bleeding
occurs that anticoagulation therapy discontinue and a new agent replace dabigatran.110 In our
study, we assumed that rivaroxaban would replace dabigatran after treating the bleeding.
Rivaroxaban was chosen because it has a good safety and efficacy profile and it is taken once
daily.

The cost of an anticoagulant clinic was derived from a study that estimated the quality and costs
associated with 3 different anticoagulant clinics: pharmacist-managed, nurse-managed, and both
pharmacist and nurse-managed anticoagulant clinics.111 In this study costs were broken into 3
parts: labor expense, lab expense, and overhead cost. In our analysis we used estimates from
pharmacist-managed anticoagulant clinics as we are more interested in the pharmacist role in
these clinics. The annual cost per patient associated with pharmacist managed anticoagulant
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clinic, adjusted to 2014, was $423. The majority of the cost was related to laboratory tests. The
cost of a physician visit was obtained from blue book (physician office visit level 3) for both
treatments.112 It was assumed patients in both branches have only 1 physician visit at the
beginning of the treatment for either referral to anticoagulant clinic or an annual prescription for
dabigatran.

The cost of treating each event was obtained from Healthcare Cost and Utilization Project
(HCUP) by using relevant Diagnosis-Related Group codes (DRG) (Table 3.4).113 The cost of
fatal MI was based from HCUP by using the associated DRG code of fatal MI (DRG 283). Due
to lack of DRG and ICD-9 codes for fatal IS, ICH, and GI bleeding, it was assumed that the cost
of death associated with these events is similar to cost of death from any cause which was
estimated from Shah SV, et al study.97 In that study, the researchers assumed that the cost of
death from any cause was equal to $10,000. Because this number is considered reasonable when
comparing it to cost of fatal MI, it was used in our analysis as cost of death from any cause, fatal
IS, fatal ICH, or fatal GI bleeding.

All the costs, from different years, where inflated to 2014 $US by using the US Healthcare
inflation rate from Bureau of Labor Statistics.114 Because the time horizon of this study is
assumed to be 1 year, there was no need for discounting costs and outcomes.100
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Section 3.4: Sensitivity analysis
Due to the uncertainty of the input values in the model, several sensitivity analyses were
performed. Sensitivity analysis allows us to test the impact of uncertainty of the estimate values
and model assumptions and how it affects the result of the analysis. The more similar the results
of sensitivity analysis to the base case results, the greater the confidence we will have in our
analysis.

One way sensitivity analysis was performed on all the probability, utility and cost variables over
plausible ranges presented in Table (3.1, 3.2, and 3.3). The values of ranges were obtained from
previous literature by using 95% CI if available, or by calculating a range of 20% in each
direction.

The 95% confidence interval (CI) of anticoagulant clinic cost was calculated by using Standard
Deviation (SD) of the mean cost that was reported by the Menzin study and applying it to
equation 3.1.111 The calculated range was used then in the sensitivity analysis. Ranges of the cost
of death were derived from Shah, et al. 97 Standard Errors (SE) of mean cost for each event (MI,
fatal MI, GI bleeding, ICH, and IS) were used to calculate 95% CI by applying equation 3.1. The
Healthcare inflation rate was also applied to SD, SE, and estimated range of death to convert
them to 2014 $US.
95%CI=

Equation 3.1

Depending on the severity of dyspepsia, sometime patient will only be managed by anti-ulcer on
an outpatient basis without the need of admission. For this reason the lower limit of the range
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used in the sensitivity analysis for dyspepsia was set to be $10. The upper limit of dyspepsia
range was calculated by using the SE of mean cost reported by HCUP.

Due to the different findings regarding probabilities of developing MI in both treatment
strategies between RELY trial and FDA study , probabilities from the FDA study were used as
the upper limit in our sensitivity analysis, while the lower limit was estimated to be 20% below
the base case value.

For the remaining variables, ranges were calculated by varying estimates by ±20%, due to lack
of reporting 95% CI.

In addition two way sensitivity analysis was performed between cost of warfarin and cost of
dabigatran. Two way sensitivity analysis allow us to demonstrate impact of the two variables
when changing their values simultaneously within given ranges.

Moreover, Monte-Carlo probabilistic sensitivity analysis was performed, specifically second
order simulation (parameter level), to simultaneously address uncertainty in all the variables in
the model. Monte-Carlo allows us to calculate means of the cost, effectiveness and net monetary
benefits of each treatment option. In this study, 10,000 simulations were conducted on all the
variables. Each variable was defined based on certain distribution functions and a specific value
of its mean and SD. The beta distribution was used for events probabilities and utilities as it
ranged between 0-1. Gamma distribution was used for all cost variables. Mean of distribution for
each variable was assumed to equal the base case input value in the model. SD for distribution of

38

each estimate in the model was equal to standard error (SE) that was calculated using following
equation:
SE=

Equation 3.2

This equation used upper limit (UL) and lower limit (LL) based on range values used in the
sensitivity analysis. 115
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Figure 3.1: Schematic representation of the model
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Table 3.1: Base-case probabilities values and ranges used in sensitivity analyses
Variable

Dabigatran:
Dyspepsia
GI bleeding
ICH
IS
MI
Death
Warfarin:
Dyspepsia
GI bleeding
ICH
IS
MI
Death
Mortality:
GI bleeding
ICH
IS
MI

Base case

Probabilities ranges used in the
sensitivity analysis
Minimum
Maximum

Reference No.

0.113
0.0151
0.003
0.0092
0.0081
0.0364

0.0904
0.01208
0.0024
0.00736
0.00648
0.02912

0.1356
0.01812
0.0036
0.01104
0.0157
0.04368

16

0.058
0.0102
0.0074
0.012
0.0064
0.0413

0.0464
0.00816
0.00592
0.0096
0.00512
0.03304

0.0696
0.01224
0.00888
0.0144
0.0169
0.04956

16

0.072
0.179
0.082
0.166

0.0576
0.1432
0.0656
0.1328

0.0864
0.2148
0.0984
0.1992

83
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16
16
16
16,104
16

16
16
16
16,104
16

83
83
83

Table 3.2: Base-case utilities values and ranges used in sensitivity analyses
Variable

AF patient on
warfarin
AF patient on
Dabigatran
Dyspepsia
Non-fatal IS
Non-fatal MI
Non-fatal ICH
Non-fatal GI
Death

Base case

0.987

Utilities ranges used in the sensitivity
analysis
Minimum
Maximum
0.7896
1

0.994

0.7952

1

106

0.996
0.61
0.87
0.39
0.94
0

0.7968
0.488
0.696
0.312
0.752
0

1
0.732
1
0.468
1
0

107
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Reference
No.
105

107
107
93
107

By
definition

Table 3.3: Base-case cost values and ranges used in sensitivity analyses
Variable

Warfarin(per year)
Dabigatran (per year)
Rivaroxaban (per 6
months)
Anticoagulant clinic
Physician visit
Dyspepsia (DRG 391)
Non-fatal GI
(DRG 377)
Non-fatal IS
(DRG 61)
Non-fatal ICH
(DRG 64)
Non-fatal MI
(DRG 280)
Fatal MI
(DRG 283)
Death

Base case
($)
11
1,162
780

Cost ranges used in the sensitivity
analysis
Minimum ($)
Maximum ($)
9
14
930
1,394
624
936

423
139
9,737
14,169

148
111
9,495
13,862

698
167
9,978
14,477

111

25,435

24,457

26,413

113

15,628

15,246

16,009

113

13,997

13,683

14,310

113

15,222

14,634

15,810

113

10,908

0

21,815

97
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Reference
No.
VCU hospital
VCU hospital
VCU hospital

112
113
113

Table 3.4: DRG codes and corresponding definitions
DRG code

Definition

DRG 391

Esophagitis, gastrointestinal & misc. digest disorders w mcc*

DRG 377

GI hemorrhage w mcc*

DRG 61

Acute ischemic stroke w use of thrombolytic agent w mcc*

DRG 64

Intracranial hemorrhage or cerebral infarction w mcc*

DRG 280

Acute myocardial infarction, discharged alive w mcc*

DRG 283

Acute myocardial infarction, expired w mcc*

*w mcc: with major comorbidity\complication
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Chapter IV: Results
Section 4.1: Base case analysis
In the base case analysis warfarin therapy in an anticoagulant clinic resulted in lower QALYs
with a value of 0.934, while 150 mg BID dabigatran resulted in 0.948 QALYs (Table 4.1). Total
costs were $2,222 for warfarin therapy supported by anticoagulation clinic management, and
$3,394for dabigatran provided according to standard of care. Therefore, dabigatran resulted in a
gain of 0.014 QALYS at an additional cost of $1,172. The ICERs for dabigatran compared with
warfarin therapy was $82,793 per QALY saved (Note: 1,172/0.014 will not equal 82,793 due to
rounding issue).

Based on willingness to pay threshold of $50,000 per QALY saved, the ICER for dabigatran is
not considered to be cost effective, so warfarin treatment provided as part of pharmacistmanaged anticoagulant clinic is considered more cost effective.

In addition to ICER, the Net Monetary Benefit (NMB) is another method that can be used to
determine the cost effective strategy. The value of NMB enables us to choose the most cost
effective strategy based on the combination of cost, effectiveness and willingness to pay. The
NMB is the difference between the monetary value of effectiveness measure (expected QALYs
multiplied by the WTP value) and total expected costs (equation 4.1).116 The advantage of NMB
is that it enables us to quantify the net benefit (in term of money) for each strategy.117
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It is calculated by converting the effectiveness (in our case QALYs) into monetary value by
multiplying it by WTP, and then subtracted from cost associated with the strategy (equation
4.1).118 The strategy with the higher NMB is the most cost effective one. Based on our analysis
warfarin therapy with an anticoagulant clinic is cost effective compare to dabigatran as it has
higher NMB value compared to dabigatran ($44,471 for warfarin vs. $44,006 for dabigatran).
The NMB is considered a better method, compared to ICER, to determine cost effectiveness
strategywhentherearesmalldifferencesineffectiveness(asinouranalysisΔQALYs=0.014).118
Another advantage of NMB over ICER is that it helps us to rank strategy from most cost
effective to least.119
NMB = (E × WTP) – C (Equation 4.1)
(Where E = effectiveness; WTP = willingness-to-pay threshold; C = cost)

NMB (for warfarin within anticoagulant clinic) = (0.934×$50,000) – $2,222= $44,471
NMB (for dabigatran 150mg BID) = (0.948 ×$50,000) – $3, 394 = $44,006

Section 4.2: One-way and two-way sensitivity analyses
A tornado diagram (figure 4.3) is a bar chart of the results of a series of one-way sensitivity
analyses which illustrate the variables with the most impact on the results of the model. The most
influential cost variables were cost of death, cost of dyspepsia and cost of anticoagulant clinic.
Important outcomes in the model were the probability of death associated with warfarin and
utility values of AF patients on warfarin and utilities for dyspepsia.
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Based on the tornado diagram, one way sensitivity analyses were done for the most influential
variables with the higher impact on the model over plausible ranges. Varying the utilities of AF
patients on warfarin had an impact on ICER value. If the value for utility of patients on warfarin
was 0.947 or lower, the ICER value for dabigatran will be lower than WTP, and so the results
will be favored toward dabigatran (Table 4.2). Net Benefit (NB) graph enable us to identify
exactly threshold in which below it the result will change. The NB graph demonstrates the one
way sensitivity analysis, in term of NMB. The NB graph is combination of effectiveness, cost
and the willingness to pay (presented as NMB on y axis). In this graph the net monetary benefit
(NMB) is being analyzed as a variable, while the values of utility of warfarin patient being
change over the plausible range. The strategy with the higher net benefits is the more cost
effective. When running the sensitivity analysis, the model will be recalculate five times over the
plausible range of utility of warfarin patient (4 intervals) (Table 4.3).120 The values in the table
(4.3) is then plotted to give us NB graph. NB Graph (Figure 4.4) tells us that if the utility of AF
patients on warfarin is 0.976 or lower then it is a better to choose dabigatran therapy, and vice
versa. For the utility of dyspepsia, changing the inputs values over the plausible range did not
differ from the base case results.

A one way sensitivity analysis was also conducted on cost of death and the results were almost
similar to the base case analysis. Moreover, varying values of cost of anticoagulant clinic over
their 95% CI did not influence the ICER values of dabigatran compared to warfarin therapy from
the base case analysis. On the other hand, changing the values of cost of dyspepsia over plausible
ranges had an impact on the ICER value (Table 4.4). NB graph for one way sensitivity analysis
of cost of dyspepsia shows that if the cost for treating dyspepsia was $1,294 or less then
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dabigatran will be more cost effective strategy compared to warfarin within anticoagulant clinic
(Figure 4.5).

Another one way sensitivity analysis was performed for the probability of death associated with
warfarin therapy over ±20% range, and result indicates that it did have an impact over ICER
value (Table 4.5). When the probability of death associated with warfarin reaches 0.049 or
higher, then the results will be favored to dabigatran to be cost effective compared to warfarin
(Figure 4.6)

Finally, due to the differences between RELY trial and FDA study regarding probabilities of
developing MI on both strategies, a one way sensitivity analysis was conducted by varying
values of probability of MI for dabigatran and then for warfarin over plausible ranges to include
the same probability value from FDA study. Both sensitivity analyses were similar to base case
analysis.

The two-way sensitivity analysis for the cost of warfarin and the cost of dabigatran indicated that
warfarin treatment within pharmacist-managed anticoagulant clinic is dominated over dabigatran
150mg BID over their plausible ranges.

Section 4.3: Probabilistic sensitivity analysis
The mean cost, effectiveness, and NMB of each strategy derived from Monte Carlo simulation
were almost similar to the base case analysis (Table 4.6). Using a WTP threshold of $50,000 per
QALY gained, almost 86.75% of calculations prefer treatment with the warfarin in anticoagulant
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clinics compared to 13.25% of the simulation to dabigatran 150mg (figure 4.7). These
percentages agree with our base case analysis. Moreover, we can be more confident by looking
at the cost effectiveness acceptability curve and by setting a range of WTP between 0 to
$100,000.This graph tells us the percentage of iterations that prefer each strategy based on
different values of WTP. Looking at acceptability curve (figure 4.8), even when WTP set to
$100,000 still treatment of warfarin in anticoagulant clinic is preferred compared to Dabigatran
therapy.
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Figure 4.1: Schematic representation of model with base case results

$2,222/0.934 QALY

$3,394/0.948 QALY
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Table 4.1: Base case results
Strategy

Cost
($)

Warfarin in
2,222
anticoagulant
clinic
Dabigatran
3,394
150mg BID

Incremental cost
($)

Effectiveness
(QALY)

Incremental
effectiveness
(QALY)

0.934

1,172

Cost/effectiveness

ICER*
($/QALY)

2,379

0.948

0.014

*ICER: Incremental cost effectiveness ratio
**NMB: Net Monetary Benefit
***Note: 1,172/0.014 will not equal 82,793 due to rounding issue
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3,581

NMB**
($)
44,471

82,793***

44,006

Table 4.2: One way sensitivity analysis results for utility of AF patients on warfarin
Utility of AF
patients on
warfarin
0.7896

0.8422

0.8948

0.9474

1.0

Strategy

Cost
($)

Incremental cost
($)

Effectiveness
(QALY)

ICER*
($/QALY)

NMB**
($)

0.763

Incremental
effectiveness
(QALY)
0.00

Warfarin in
anticoagulant
clinic
Dabigatran
150mg BID
Warfarin in
anticoagulant
clinic
Dabigatran
150mg BID
Warfarin in
anticoagulant
clinic
Dabigatran
150mg BID
Warfarin in
anticoagulant
clinic
Dabigatran
150mg BID
Warfarin in
anticoagulant
clinic
Dabigatran
150mg BID

2,222

0.00

0.00

35,936

3,394

1,172

0.948

0.185

6,342

44,006

2,222

0.00

0.809

0.000

0.000

38,210

3,394

1,172

0.948

0.139

8,412

44,006

2,222

0.00

0.854

0.000

0.000

40,484

3,394

1,172

0.948

0.094

12,488

44,006

2,222

0.00

0.900

0.000

0.000

42,759

3,394

1,172

0.948

0.048

24,222

44,006

2,222

0.00

0.945

0.000

0.000

45,033

3,394

1,172

0.948

0.003

401,533

44,006
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Table 4.3: Net Benefit table for sensitivity analysis of utility of warfarin patients
Value of utility of warfarin
patient
0.790
0.842
0.895
0.947
1.000

Net Monetary Benefit (NMB) ($)
Warfarin within anticoagulant
Dabigatran 150 mg BD
clinic
35,936
44,006
38,210
44,006
40,484
44,006
42,759
44,006
45,033
44,006
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Table 4.4: Net Benefit table for sensitivity analysis of cost of dyspepsia
Cost of
dyspepsia
($)
10

2,502

4,994

7,486

9,978

Strategy

Cost
($)

Incremental cost ($)

Effectiveness
(QALY)

ICER*
($/QALY)

NMB**
($)

0.934

Incremental
effectiveness
(QALY)
0.00

Warfarin in
anticoagulant
clinic
Dabigatran
150mg BID

1,658

0.00

0.00

45,035

2,295

637

0.948

0.014

45,014

45,105

Warfarin in
anticoagulant
clinic
Dabigatran
150mg BID
Warfarin in
anticoagulant
clinic
Dabigatran
150mg BID
Warfarin in
anticoagulant
clinic
Dabigatran
150mg BID
Warfarin in
anticoagulant
clinic
Dabigatran
150mg BID

1,802

0.00

0.934

0.000

0.000

44,891

2,577

774

0.948

0.014

54,693

44,824

1,947

0.00

0.934

0.000

0.000

44,746

2,859

912

0.948

0.014

64,372

44,542

2,091

0.00

0.934

0.000

0.000

44,601

3,140

1,049

0.948

0.014

74,051

44,261

2,236

0.00

0.934

0.000

0.000

44,457

3,422

1,186

0.948

0.014

83,730

43,979
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Table 4.5: One way sensitivity analysis results for probability of death associated with warfarin therapy
probability of
death
associated with
warfarin
therapy
0.033

0.037

0.041

0.045

0.049

Strategy

Cost
($)

Incremental cost
($)

Effectiveness
(QALY)

Incremental
effectiveness
(QALY)

ICER*
($/QALY)

NMB**
($)

Warfarin in
anticoagulant
clinic
Dabigatran
150mg BID
Warfarin in
anticoagulant
clinic
Dabigatran
150mg BID
Warfarin in
anticoagulant
clinic
Dabigatran
150mg BID
Warfarin in
anticoagulant
clinic
Dabigatran
150mg BID
Warfarin in
anticoagulant
clinic
Dabigatran
150mg BID

2,132

0.00

0.942

0.00

0.00

44,968

3,394

1,262

0.948

0.006

210,128

44,006

2,177

0.00

0.938

0.000

0.000

44,719

3,394

1,217

0.948

0.01

120,725

44,006

2,222

0.00

0.934

0.000

0.000

44,471

3,394

1,172

0.948

0.014

82,793

44,006

2,267

0.00

0.93

0.000

0.000

44,222

3,394

1,127

0.948

0.018

61,817

44,006

2,312

0.00

0.926

0.000

0.000

43,973

3,394

1,082

0.948

0.022

48,505

44,006
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Table 4.6: Results of Monte Carlo probabilistic sensitivity analysis
Attribute

Statistics

Warfarin with anticoagulant clinic

Dabigatran 150mg BID

Cost

Mean

2224

3,421

SD*

297.58

276.6

Mean

0.934

0.948

SD*

0.047

0.041

Mean

44,480

43,987

SD*

2,350.83

2,093.77

Effectiveness

NMB**

*SD: Standard deviation
**NMB: Net Monetary Benefit
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Figure 4.2: Base case cost effectiveness graph
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Figure 4.1: Tornado Diagram demonstrate influence of each variable on the base case results
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Figure 4.4: Net benefit graph for one way sensitivity analysis for utility of AF patients on
warfarin
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Figure 4.5: Net benefit graph for one way sensitivity analysis for cost of dyspepsia
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Figure 4.6: Net benefit graph for one way sensitivity analysis for probability of death associated
with warfarin therapy
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Figure 4.7: Strategy selection chart demonstrate percentage of iterations that prefer each strategy
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Figure 4.8: Cost effectiveness acceptability curves representing percentage of iterations that
prefer each strategy according to different values of WTP
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Chapter V: Discussion

In this study we assessed cost effectiveness of Dabigatran 150mg BID compared to adjusted dose
of warfarin within pharmacist-managed anticoagulant clinics. Dabigatran was chosen to
represent NOACs, as it is the most studied NOAC and the first one introduced into the US
market. According to this study, for AF patientage≥65yearsoldwith higher risk of stroke
(CHADS2 score >2), it is more cost effective to treat them with warfarin within an anticoagulant
clinic rather than dabigatran. The base case analysis showed that neither treatment was dominant.
However, the ICER for dabigatran was over $82,000 per QALY saved exceeded the established
WTP threshold of $50,000, making warfarin treatment at anticoagulant clinics a more cost
effective option. Moreover, warfarin treatment resulted in higher net monetary benefits (NMB)
compared to dabigatran therapy. The base case analysis revealed that for every 100 patients
treated by dabigatran, there is almost a 1.4 QALY gained compared to those treated with
warfarin and attending anticoagulant clinic. On the other hand, treatment with dabigatran cost
approximately an extra $1,172 per patient compared to warfarin in anticoagulant clinic.
This analysis was found to be sensitive to utility of patients on warfarin, which determined by
control of INR levels and time spent within therapeutic INR ranges. It suggested that if the utility
of warfarin patient dropped lower than 0.947, then the results will change and be to favor
dabigatran compare to warfarin.
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Also the sensitivity analysis indicates that cost of treating dyspepsia and probability of death
associated with warfarin therapy have an impact on the ICER value.

Moreover, the analysis revealed that the cost of anticoagulant clinic did not have an impact on
the overall findings. Varying cost of anticoagulant clinic over plausible ranges did not decrease
the ICER associated with dabigatran below WTP threshold ($50,000/QALY). This is considered
interesting finding, as it addressed a crucial component of our research. In this analysis, we were
trying to assess importance of anticoagulant clinic after introduction of NOACs. Based on this
result, despite the fact that NOACs provide a greater QALYs compared to warfarin, they may
not represent an acceptable economic value. In other words, the relative advantage of NOACs
over the warfarin depends mainly on quality of control of warfarin therapy and how well it is
managed. Basically, the important factor that can affect the preferred treatment option is not the
cost of anticoagulant clinic associated with warfarin therapy, but the level of INR control and the
impactonqualityofpatients’life.

In most previous studies, cost effectiveness analyses have concluded that dabigatran is more cost
effective compared to warfarin. Freeman et al. reported that dabigatran may be cost effective
compared to warfarin within ICER value of $45,372 per QALY gained with dabigratran.88 A
model by Kamal et al. yielded a similar conclusion with an ICER estimate of $25,000 per QALY
gained for dabigatran.93 Shah et al. estimated an ICER of $86,000 per QALY gained for
dabigatran compared to warfarin.97
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The primary difference between the conclusions in this analysis and similar published economic
studies resulted from assumptions about the patient population being treated. They all concluded
that dabigatran is only cost effective if the INR control is poor.93,97 In these two studies (by Shah
et al. and Kamal et. Al.) they incorporated time in therapeutic range as a variable in their
sensitivity analysis and found that that INR control had impact on the base case findings. This
means that warfarin might be more economical if the INR control is excellent, which may be the
case with most of anticoagulant clinics.10,121

There are other reasons why our results differed in finding that warfarin treatment with
anticoagulant clinic is preferred over dabigatran for AF patients with higher risk of stroke. One
reason is that our analysis used a decision tree with a time period of one year, while other studies
used Markov models assessing lifetime outcomes and costs. The cost calculation and the
probabilities of developing any adverse event can be affected by the time horizon of the study.
Also the type of economic model used to analyze data can have an impact over the result due to
the differences in the underlined assumptions and model design.

Another reason is that in our study we assumed that patients treated with warfarin would be
within therapeutic range and have excellent INR control for all the study period. Most of the
previously discussed studies reported that their results will only be applicable if the INR control
was poor. This is because the efficacy and the safety of warfarin therapy depend mainly on the
level of INR control and the time spent within therapeutic ranges.
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Previous to the appearance of NOACs, studies of anticoagulant clinics showed them to be
significantly better at controlling anticoagulation than usual care.29,31,40,54,61,72 For example,
Nichol et al. showed that time spent in therapeutic ranges was significantly longer for the
patients attending pharmacist-managed anticoagulant clinics compared to usual care (68.14% vs.
42.07%, p<0.001).61 Therefore, NOACs are likely to be economically superior if warfarin is not
monitored in anticoagulation clinics or some other similar program.

In addition to the findings of this study, there are other reasons to limit its use in replacing
warfarin in real world practice. One is that most evidence for its use comes from specific
populations ofAFpatients≥65yearsoldwithnorenalfailuredisorder;whileintherealworld
most of the AF patients are 75 and older with renal disorder and other complications.122 Some
clinicians still hesitate of prescribing dabigatran in those patients without clinic evidence of
effectiveness and safety.123 Moreover, most AF patients are elderly with chronic conditions and
are maintained on warfarin, which make it difficult to replace with new drug like dabigatran. In
practice, NOACs are dispensed more often for deep vein thrombosis (DVT) patients as they are
relatively younger and do not usually need chronic use of medications.

There is a crucial need for real world data treatments for AF patients. Each AF patient in real
practice is unique and choiceoftheappropriatedrugdependsonnumerousfactors:patient’s
clinicalconditions,clinicianandpatient’spreference,andcost.5 There are several guidelines for
selecting appropriate anticoagulant agents such as AHA/ACC/HRS Guideline for the
management of patients with AF. However, there is scarce clinical information for appropriate
management of major bleeding specially with NOACs. Moreover there is no clear guideline of
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when to switch to another agent and what type of agent. This is can be due to complexity of AF
patients, and that each scenario could be treated with different way.

In this study we were able to show that anticoagulant clinics are still economically viable after
the introduction of NOACs. Anticoagulant clinics are still needed to monitor warfarin treatments
for AF patients who may not benefit from NOACs.

There are several limitations of our study that need to be addressed. First, all of the event
probabilities where derived from a single clinical trial. This is because the RELY trial is the only
published clinical trial that directly compared warfarin and dabigatran. We tried to test this
limitation by using some data in our sensitivity analyses from an FDA study report that looked at
adverse events probabilities between dabigatran and warfarin. Second, we assumed that
pharmacist-managed anticoagulant clinics were able to keep INR for all warfarin patients within
therapeutic ranges similar to those in the RELY study. In the real world the percentage of INR
control and time spent in the therapeutic range varies. Estimates of anticoagulant clinic patients
within therapeutic ranges vary from 50.2-68.14%, while the patients in the RELY clinical trial
(64%). 16,29,40,61 This can have an impact on our results as we might overestimate effectiveness of
patients in anticoagulant clinic. Third, we assumed that all patients in both treatment options had
the same medication adherence rates. This might differ from the real world, because each option
differed in dosage regimen, safety profile, and monitoring. This assumption was made because
there was insufficient data regarding level of adherence of NOACs in real world. This is can be
due to the fact that NOACs are still considered new and there are smaller numbers of patients
treated with them compared to those treated with warfarin. One point that we can add here is
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that because dabigatran patients were not followed in anticoagulants services, they may have
lower adherence rate compare to those on warfarin and attend anticoagulant clinic. This can
impact on our results as we might overestimate effectiveness of dabigatran in real world.
Another limitation of the study is that we assumed that rivaroxaban would replace dabigatran in
case of developing major bleeding. This assumption was made due to limited clinical
information for appropriate management of major bleeding specially with NOACs. Moreover,
although this study was done from societal perspective, we only captured direct medical cost
associated with each treatment option. In this analysis, the long term effect of both treatments
was not addressed as our time horizon was only for one year. This is due to the lack of data
regarding long term effect of the NOACs. Finally, as the case with most of this type of analysis,
data were driven from different sources; however we tried to answer this by running multiple
sensitivity tests.

In conclusion, warfarin treatment associated with pharmacist-managed anticoagulant clinic is an
economicallyviablestrategyforAFpatientsage≥65 years old and with higher risk of stroke
(CHADS2 score≥2). This result is highly affected by patient utility preferences for warfarin
treatment, which determined by control of INR levels and time spent within therapeutic INR
ranges. Based on the results, there is a need to focus on improving the role of pharmacist in these
clinics and try to recruit more of AF patient to attend the anticoagulant clinic in order to enhance
therapeutics outcomes and reduce complications associated with warfarin treatment. Because this
model is built upon clinical trial data, future studies may be needed to assess effectiveness and
safety of NOACs compared to warfarin within anticoagulant clinic in real world settings.
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Appendix A

Figure A.1: Schematic representation of model with payoffs
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Appendix B

Table B.1: Resource utilized and cost associated with each branch in the descion tree for warfarin patients within
pharmacist-managed anticoagulant clinic
Path of each branch in
the tree
Well state

Cost of
Cost of 1
Cost of
warfarin
physician visit anticoagulant
(per year) ($)
($)
clinic ($)
11
139
423

Cost of treating
adverse event
($)
-

Total cost
($)
573

Non-fatal IS

11

139

423

25,435

26,008

Fatal IS

11

139

423

10,908

11,481

Non-fatal ICH

11

139

423

15,628

16,201

Fatal ICH

11

139

423

10,908

11,481

Non-fatal GI bleeding

11

139

423

14,169

14,742

Fatal GI bleeding

11

139

423

10,908

11,481

Non-fatal MI

11

139

423

13,997

14,570

Fatal MI

11

139

423

15,222

15,795

Dyspepsia

11

139

423

9,737

10,310

Death from any cause

11

139

423

10,908

11,481
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Table B.2: Resource utilized and cost associated with each branch in the decision tree for dabigatran patients
Path of each branch
in the tree

Cost of
dabigatran
(6 months)
($)
-

Cost of
rivaroxaban
(6 months)
($)
-

Cost of 1
physician
visit
($)
139

Cost of
treating
adverse event
($)
-

Total cost
($)

Well state

Cost of
dabigatran
(per year)
($)
1,162

Non-fatal IS

1,162

-

-

139

25,435

26,736

Fatal IS

1,162

-

-

139

10,908

12,209

Non-fatal ICH

-

581

780

139

15,628

17,128

Fatal ICH

1,162

-

-

139

10,908

12,209

Non-fatal GI
bleeding
Fatal GI bleeding

-

581

780

139

14,169

15,669

1,162

-

-

139

10,908

12,209

Non-fatal MI

1,162

-

-

139

13,997

15,298

Fatal MI

1,162

-

-

139

15,222

16,523

Dyspepsia

1,162

-

-

139

9,737

11,038

Death from any
cause

1,162

-

-

139

10,908

12,209
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1,301

